Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease : a systematic review and meta-analysis
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned about a potential risk of pregnancy specifically in the case of hormone receptor-positive breast cancer.
MATERIALS AND METHODS: A systematic literature search of Medline, Embase and Cochrane library with no language or date restriction up to 31 March 2023 was carried out. To be included, articles had to be retrospective and prospective case-control and cohort studies as well as clinical trials comparing survival outcomes of premenopausal women with or without a pregnancy after prior diagnosis of hormone receptor-positive breast cancer. Disease-free survival (DFS) and overall survival (OS) were the outcomes of interest. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Study protocol is registered in PROSPERO (n. CRD42023394232).
RESULTS: Out of 7796 screened studies, 8 were eligible to be included in the final analysis. A total of 3805 patients with hormone receptor-positive invasive early breast cancer were included in these studies, of whom 1285 had a pregnancy after breast cancer diagnosis. Median follow-up time ranged from 3.8 to 15.8 years and was similar in the pregnancy and non-pregnancy cohorts. In three studies (n = 987 patients) reporting on DFS, no difference was observed between patients with and those without a subsequent pregnancy (HR 0.96, 95% CI 0.75-1.24, P = 0.781). In the six studies (n = 3504 patients) reporting on OS, patients with a pregnancy after breast cancer had a statistically significant better OS than those without a pregnancy (HR 0.46, 95% CI 0.27-0.77, P < 0.05).
CONCLUSIONS: This systematic review and meta-analysis of retrospective cohort studies provides updated evidence that having a pregnancy in patients with prior history of hormone receptor-positive invasive early breast cancer appears safe without detrimental effect on prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
ESMO open - 8(2023), 6 vom: 16. Dez., Seite 102031 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arecco, L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 11.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2023.102031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363714472 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363714472 | ||
| 003 | DE-627 | ||
| 005 | 20240114233803.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2023.102031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM363714472 | ||
| 035 | |a (NLM)37879234 | ||
| 035 | |a (PII)S2059-7029(23)01272-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arecco, L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease |b a systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned about a potential risk of pregnancy specifically in the case of hormone receptor-positive breast cancer | ||
| 520 | |a MATERIALS AND METHODS: A systematic literature search of Medline, Embase and Cochrane library with no language or date restriction up to 31 March 2023 was carried out. To be included, articles had to be retrospective and prospective case-control and cohort studies as well as clinical trials comparing survival outcomes of premenopausal women with or without a pregnancy after prior diagnosis of hormone receptor-positive breast cancer. Disease-free survival (DFS) and overall survival (OS) were the outcomes of interest. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Study protocol is registered in PROSPERO (n. CRD42023394232) | ||
| 520 | |a RESULTS: Out of 7796 screened studies, 8 were eligible to be included in the final analysis. A total of 3805 patients with hormone receptor-positive invasive early breast cancer were included in these studies, of whom 1285 had a pregnancy after breast cancer diagnosis. Median follow-up time ranged from 3.8 to 15.8 years and was similar in the pregnancy and non-pregnancy cohorts. In three studies (n = 987 patients) reporting on DFS, no difference was observed between patients with and those without a subsequent pregnancy (HR 0.96, 95% CI 0.75-1.24, P = 0.781). In the six studies (n = 3504 patients) reporting on OS, patients with a pregnancy after breast cancer had a statistically significant better OS than those without a pregnancy (HR 0.46, 95% CI 0.27-0.77, P < 0.05) | ||
| 520 | |a CONCLUSIONS: This systematic review and meta-analysis of retrospective cohort studies provides updated evidence that having a pregnancy in patients with prior history of hormone receptor-positive invasive early breast cancer appears safe without detrimental effect on prognosis | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a hormone receptor-positive disease | |
| 650 | 4 | |a oncofertility | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a premenopausal patients | |
| 700 | 1 | |a Blondeaux, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bruzzone, M |e verfasserin |4 aut | |
| 700 | 1 | |a Latocca, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Mariamidze, E |e verfasserin |4 aut | |
| 700 | 1 | |a Begijanashvili, S |e verfasserin |4 aut | |
| 700 | 1 | |a Sokolovic, E |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, G |e verfasserin |4 aut | |
| 700 | 1 | |a Scavone, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ottonello, S |e verfasserin |4 aut | |
| 700 | 1 | |a Boutros, A |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz-Luis, I |e verfasserin |4 aut | |
| 700 | 1 | |a Saura, C |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, R A |e verfasserin |4 aut | |
| 700 | 1 | |a Demeestere, I |e verfasserin |4 aut | |
| 700 | 1 | |a Azim, H A |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a de Azambuja, E |e verfasserin |4 aut | |
| 700 | 1 | |a Peccatori, F A |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, L |e verfasserin |4 aut | |
| 700 | 1 | |a Partridge, A H |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 8(2023), 6 vom: 16. Dez., Seite 102031 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:6 |g day:16 |g month:12 |g pages:102031 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2023.102031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 6 |b 16 |c 12 |h 102031 | ||